We'll show how many patients carry the mutation, then pressure the government for more.
Em um país onde o acesso à saúde ainda é profundamente marcado pela desigualdade, o Brasil dá um passo simbólico e concreto ao incorporar ao SUS os testes genéticos para mutações BRCA1 e BRCA2, responsáveis por elevar significativamente o risco hereditário de câncer de mama. O que antes custava até 50 mil reais e permanecia restrito a clínicas particulares torna-se, agora, um direito de mais de 200 milhões de pessoas — não por generosidade repentina, mas porque a tecnologia finalmente tornou o custo sustentável. A medida não resolve tudo, mas abre uma fresta: entre o diagnóstico tardio e a prevenção informada, entre a doença que surpreende e aquela que pode ser antecipada.
- Mulheres com histórico familiar de câncer de mama ou ovário enfrentavam, até agora, a cruel escolha entre pagar milhares de reais por um teste genético ou permanecer na incerteza.
- A publicação da portaria no Diário Oficial impõe ao SUS um prazo de 180 dias para estruturar a oferta dos testes — uma corrida contra a burocracia em um sistema que atende mais de dois séculos de pessoas.
- Especialistas comemoram, mas alertam: o teste sem a cirurgia preventiva, a reconstrução mamária e as terapias-alvo é como entregar um mapa sem o caminho — a informação existe, mas os recursos para agir sobre ela ainda não estão garantidos.
- O caso de Angelina Jolie, em 2013, tirou o teste do anonimato médico; agora, são os dados epidemiológicos gerados pelo próprio SUS que poderão pressionar o governo a ampliar a cobertura para os procedimentos que se seguem ao diagnóstico genético.
- O presidente da Sociedade Brasileira de Mastologia vê na medida uma alavanca estratégica: quanto mais mulheres testadas, mais sólido o argumento para incluir cirurgias preventivas e medicamentos específicos no sistema público.
O Sistema Único de Saúde passará a oferecer, nos próximos seis meses, testes genéticos capazes de identificar mutações nos genes BRCA1 e BRCA2 — marcadores hereditários que elevam substancialmente o risco de câncer de mama e ovário. A medida, publicada em portaria no Diário Oficial, representa uma virada de acesso: até agora, o exame estava confinado às clínicas particulares, com preços entre 1.000 e 3.000 reais.
O que tornou a integração ao SUS viável não foi um gesto político isolado, mas uma transformação econômica silenciosa. Há uma década, o mesmo teste custava mais de 50 mil reais. Hoje, com o avanço tecnológico e o aumento da concorrência, algumas clínicas já o oferecem por cerca de 1.500 reais. O barateamento abriu a janela para que um sistema que atende mais de 200 milhões de pessoas pudesse absorver o custo.
As consequências de um resultado positivo vão além da pessoa testada. Ele pode redirecionar toda a trajetória médica de uma mulher — indicando cirurgias preventivas, intensificando o rastreamento ou orientando terapias específicas. E, igualmente importante, alerta familiares que compartilham a mesma mutação, permitindo decisões informadas antes que a doença se manifeste.
Mas a celebração vem acompanhada de ressalvas. O SUS oferecerá o teste, mas ainda não cobre as cirurgias preventivas que frequentemente se seguem a um diagnóstico positivo. Clínicas privadas já disponibilizam painéis mais amplos, que sequenciam centenas de genes além do BRCA1 e BRCA2. A oferta pública é um começo, não uma solução completa.
Para o Dr. Guilherme Novita Garcia, presidente da Sociedade Brasileira de Mastologia, a portaria é uma abertura estratégica. Com milhares de mulheres sendo testadas pelo SUS, o Ministério da Saúde terá dados concretos sobre a prevalência das mutações no país — e esses dados se tornam argumento. 'Vou ter mais embasamento para pressionar o governo a incluir cirurgia preventiva, reconstrução mamária e medicamentos específicos', afirmou. O teste, em sua avaliação, é apenas o primeiro de muitos passos ainda necessários para democratizar de fato o cuidado oncológico no Brasil.
Brazil's public health system will begin offering genetic testing for hereditary breast cancer within the next six months. A directive published this week in the official government gazette requires the SUS—the country's unified public health network—to provide testing that identifies mutations in the BRCA1 and BRCA2 genes, which signal a substantially elevated inherited risk for the disease. The move represents a significant expansion of access to a test that has until now remained largely confined to private clinics, where it costs between 1,000 and 3,000 reais.
The test gained international prominence in 2013 when American actress Angelina Jolie announced she carried a BRCA1 mutation and chose to undergo preventive mastectomy. Both her mother and aunt had died of cancer. That public disclosure transformed the test from medical obscurity into something recognizable to millions. What made the SUS integration possible, however, was not celebrity endorsement but economics. The test has become dramatically cheaper. A decade ago it cost more than 50,000 reais. Today, private clinics charge around 1,500 reais in some locations. As technology improves and competition increases, the price continues to fall, making it feasible for a public system serving over 200 million people to absorb the cost.
The implications extend beyond the person tested. A positive result can reshape a woman's medical trajectory—potentially leading to preventive surgery, intensified screening, or targeted therapies. Equally important, it alerts relatives who carry the same mutation but have not yet developed disease, allowing them to make informed decisions about their own health. The BRCA mutations also increase risk for ovarian cancer and, to a lesser degree, other malignancies, including in men. For families with a history of early-onset breast or ovarian cancer, the test can be the difference between reactive treatment and proactive prevention.
Yet the celebration among specialists and patient advocates comes with a notable caveat. While the SUS will now offer BRCA testing, it does not yet cover the preventive surgeries that often follow a positive result—the kind of procedure Jolie underwent. Private clinics already offer more comprehensive panels that sequence hundreds of additional genes beyond BRCA1 and BRCA2, providing a fuller picture of inherited cancer risk. The public system's initial offering is narrower, a first step rather than a complete solution.
Dr. Guilherme Novita Garcia, president of the Brazilian Society of Mastology, views the testing mandate as a strategic opening. Once the SUS begins testing thousands of women, the health ministry will have concrete data on how many Brazilians carry these mutations. That epidemiological foundation becomes leverage. "We'll be able to show how many patients in Brazil have this mutation," Garcia said. "Then I have more grounds to push the government to include preventive surgery, breast reconstruction, and specific medications for patients who carry the mutation." In his assessment, the test is merely the first of many steps still needed to truly democratize breast cancer treatment across the country.
International guidelines, published last year by the American Society of Clinical Oncology with input from Brazilian experts, recommend genetic testing for women 65 and younger who have recently been diagnosed with breast cancer. For older women, personal or family history, ancestry, or eligibility for certain targeted therapies may warrant testing. The guidelines also recommend testing for triple-negative breast cancers and for men with personal or family histories suggestive of pathogenic variants. The SUS directive aligns with these standards, establishing a baseline of care that Brazil's public system has not previously offered. What remains to be seen is whether this opening will lead to the broader policy shifts Garcia and others are advocating for—the surgeries, reconstructions, and medications that would complete the picture of hereditary cancer care.
Notable Quotes
The technology improves, so the test becomes cheaper. It once cost more than fifty thousand reais and now costs fifteen hundred in some places.— Dr. Guilherme Novita Garcia, president of the Brazilian Society of Mastology
We'll show how many patients in Brazil have this mutation. Then I have more grounds to push the government to include preventive surgery, breast reconstruction, and specific medications.— Dr. Guilherme Novita Garcia
The Hearth Conversation Another angle on the story
Why did this take so long? Genetic testing for inherited cancer risk has existed for years.
The technology was there, but the cost was prohibitive for a public system. When the test first emerged, it cost fifty thousand reais. That's simply not sustainable for a government health program serving millions of people. The price had to fall first.
And it did fall. What changed?
Competition, scale, improved sequencing technology. The same forces that make any technology cheaper over time. Once it hit around fifteen hundred reais, the math became different. Suddenly, incorporating it into the public system became a realistic conversation.
So this is really about economics, not medicine?
It's both. The medicine was always sound. But medicine without access is just theory. What changed is that access became affordable enough to be real.
The article mentions that private clinics test for hundreds of genes, not just BRCA1 and BRCA2. Why is the public system starting with just those two?
Cost again, partly. But also clarity. BRCA mutations have the strongest evidence base for clinical action. If you carry one, you have concrete options—screening protocols, preventive surgery, targeted drugs. The broader panels are useful, but they're more complex to interpret and act on. The SUS is starting with what's most actionable.
But doesn't that leave people with other genetic risks undetected?
Yes. That's why Dr. Garcia is already talking about this as a first step. He's using the data from this initial program as evidence to argue for more comprehensive testing later. It's strategic—prove the concept, gather numbers, then expand.
What happens to someone who tests positive?
Right now, they know they're at high risk. They can pursue more aggressive screening. But if they want preventive surgery—the mastectomy that Jolie had—they'll likely have to pay for it privately. That's the gap everyone's pointing to. The test is now public. The prevention isn't.